PAVmed's Strategic Device Progress
PAVmed Advances Key Medical Devices and Commercial Milestones Following Q2 Revenue Growth
Key Points
Six-month revenue totaled $0.055 million ($55 thousand) for the six months ended June 30, 2026, signaling a measurable step-up from $0.014 million in the prior-year period.
PortIO’s first-in-human results demonstrated 100% device patency with no device-related adverse events during the quarter.
Lucid Diagnostics posted $1.5 million in EsoGuard Esophageal DNA Test revenue for Q2 2026 and processed 2,770 EsoGuard tests, with the policy adoption by multiple health plans following the first laboratory benefit manager coverage.
Veris Health’s deployment at Ohio State University’s The James cancer hospital expanded after electronic health record integration, with approximately two-thirds of planned departments onboarded and a large purchase order to support onboarding through year-end.
PAVmed remains Lucid Diagnostics’ largest common shareholder (about 15% of Lucid’s common shares outstanding) and, while it maintains around 25% voting interest in Lucid, it no longer has voting control over Lucid.
PAVmed posted $33 thousand in Q2 2026 revenue — up sharply from $6 thousand a year ago — while reporting a GAAP net loss of $5.5 million, according to TipRanks. The company ended the quarter with $3.8 million in cash and trimmed its adjusted net loss to $1.7 million after stripping out non-cash charges.
The results reflect a company moving from lab to bedside across multiple fronts. ScanX Trade reported that PAVmed advanced its implantable monitoring device toward an FDA submission, saw strong early clinical results for PortIO, and expanded a key hospital deployment — all while keeping costs tight.
PortIO Posts Perfect Early Results in First Human Use
PAVmed's PortIO device — a small implantable port for delivering medication — showed 100% device patency in its first-in-human study. That means every device stayed open and working. There were zero device-related side effects, according to TipRanks.
The company is pushing PortIO toward an FDA submission. TradingView noted that the strong early data positions PAVmed to make that filing in the near term. PortIO remains one of the company's core development programs alongside Octeris, which is also receiving continued investment.
Veris Health Expands at Ohio State's Cancer Hospital
Veris Health is rolling out its remote patient monitoring platform at Ohio State University's The James, a major cancer hospital. About two-thirds of planned departments are now onboarded, ScanX Trade reported. The expansion followed successful electronic health record integration.
OSU placed a large purchase order to support onboarding through the end of 2026. TipRanks said the deal signals that Veris is accelerating its commercial rollout after months of setup. More departments are expected to go live before year-end.
Lucid Diagnostics Gains Payer Coverage and Posts $1.5M Revenue
Lucid Diagnostics, PAVmed's majority-owned subsidiary, posted $1.5 million in EsoGuard revenue for Q2 2026. EsoGuard is a DNA test for early esophageal cancer detection. Lucid processed 2,770 tests during the quarter, according to TipRanks.
Multiple health plans adopted coverage policies for EsoGuard following the first laboratory benefit manager coverage decision. TradingView noted this payer momentum could support broader commercial growth. PAVmed holds about 15% of Lucid's common shares and roughly 25% of its voting interest, but no longer controls Lucid's vote.
Six-Month Revenue Jumps but Cash Runway Stays Tight
For the first half of 2026, PAVmed recorded $55 thousand in total revenue. That compares to just $14 thousand in the same period a year earlier — nearly a fourfold jump, per ScanX Trade. The growth tracks with commercialization milestones across its subsidiaries.
Still, the company's $3.8 million cash position is slim for a multi-program medtech firm. PAVmed is managing costs carefully. Its adjusted net loss of $1.7 million shows meaningful improvement from headline GAAP figures once non-cash items — like stock compensation and depreciation — are removed, TipRanks noted.
Sentiment
Mostly PositivePublishers
11
Articles
19
Reach
30
